Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
6.7
19x
60%
—
85.47%
40%
—
5 Years
Score6.7
Net Growth19x
Net Trend60%
Net Income Consistency—
Rev Growth85.47%
Rev Trend40%
Revenue Consistency—
Rigel Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 108M to $ 294M and net income went from -$ 29M to $ 367M. Revenue increased in 2 of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 28M to $ 294M and net income went from -$ 51M to $ 367M. Revenue increased in 6 of those 10 years; net income in 7.
Rigel Pharmaceuticals Inc currently holds a 20-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 41.87 | — |
1 Year2025-08-12 | $ 34.52 | 21.29% |
5 Years2021-08-12 | $ 41.30 | 1.38% |
10 Years2016-08-12 | $ 28.10 | 49.00% |
20 Years2006-08-11 | $ 89.60 | -53.27% |
All Time2000-11-29 | $ 639.84 | -93.46% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | All Time2000-11-29 |
|---|---|---|---|---|---|---|
| Price | $ 41.87 | $ 34.52 | $ 41.30 | $ 28.10 | $ 89.60 | $ 639.84 |
| Return | — | 21.29% | 1.38% | 49.00% | -53.27% | -93.46% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 276M | $ 321M | $ 95M |
| 2025 | $ 294M | $ 367M | $ 154M |
| 2024 | $ 179M | $ 17M | $ 77M |
| 2023 | $ 116M | -$ 25M | $ 56M |
| 2022 | $ 120M | -$ 58M | $ 58M |
| 2021 | $ 149M | -$ 17M | $ 124M |
| 2020 | $ 108M | -$ 29M | $ 57M |
| 2019 | $ 59M | -$ 66M | $ 98M |
| 2018 | $ 44M | -$ 70M | $ 128M |
| 2017 | $ 4M | -$ 77M | $ 115M |
| 2016 | $ 20M | -$ 69M | $ 74M |
| 2015 | $ 28M | -$ 51M | $ 126M |
| 2014 | $ 8M | -$ 90M | $ 143M |
| 2013 | $ 7M | -$ 89M | $ 211M |
| 2012 | $ 2M | -$ 98M | $ 298M |
| 2011 | $ 4M | -$ 85M | $ 247M |
| 2010 | $ 125M | $ 37M | $ 177M |
| 2009 | $ 750K | -$ 111M | $ 133M |
| 2008 | -$ 132M | $ 134M | |
| 2007 | $ 12M | -$ 74M | $ 108M |
| 2006 | $ 33M | -$ 37M | $ 104M |
| 2005 | $ 16M | -$ 45M | $ 138M |
| 2004 | $ 4M | -$ 56M | $ 71M |
| 2003 | $ 11M | -$ 41M | $ 46M |
| 2002 | $ 15M | -$ 37M | $ 27M |
| 2001 | $ 15M | -$ 23M | $ 33M |
| IPO2000 | $ 13M | -$ 25M | $ 52M |
Explore beyond RIGL
You're looking at Rigel Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
